Weight loss drugs like Wegovy may trigger eating disorders in some patients, doctors warn
UC expert featured in NBC News article
GLP-1 drugs, sold under brand names including Ozempic and Wegovy, are growing more popular for weight loss, but experts say they can also be triggering or worsening eating disorders in some people.
NBC News highlighted a case study published by the University of Cincinnati's Susan McElroy, MD, and colleagues. A woman diagnosed with an eating disorder for 28 years and with a history of abusing medications to lose weight had been prescribed a GLP-1 drug for weight loss. The woman lost 50 pounds in nine months, but she confided that she often took more medication than prescribed “when she felt she ate too much” and was hospitalized for suicidal thoughts.
In the case study, McElroy and her coauthors said doctors should screen for eating disorders and monitor patients' weight carefully when deciding whether to prescribe a GLP-1.
McElroy, the Linda and Harry Fath endowed professor in the Department of Psychiatry & Behavioral Neuroscience in UC’s College of Medicine and chief research officer at the Lindner Center of HOPE, said she and her colleagues screen all potential patients for eating disorders, as well as depression, anxiety and substance-use disorders.
More research is needed on GLP-1's effectiveness in treating binge eating disorder specifically, McElroy added.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.